FA
FactsNotFiction
Community Contributor
Member since 2020
Views40Total number of views
Followers1Total number of followers
Comments0Total number of comments
No bio added yet
No link added
Significantly undervalued due to several years of reliance on poor UK funding options moving to US based investment.
Active Pipeline: HG-CT-1 - Hemogenyx CAR-T for R/R AML + expanding to pediatrics in H1 2025 targeting FLT3 which has recently been proven as an extremely promising and effective target. Significant interest in CAR-T treatments with each treatment 200k+, licensing deals in the range of 500m->1bn+ (including milestone payments) CDX - Building on same FLT3 target expands use of bi-specific antibody to a whole range of blood borne cancers and diseases including auto-immune.Read more
40
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
FA
UK£80
88.5% undervalued intrinsic discount
FactsNotFiction's Fair Value
Profit Margin
19.78%
Future PE
27.05x
Price in 2029
UK£0